The Health Disparities in Osteoarthritis (OA) workshop brought together OA investigators with others who have expertise in health disparities to exchange ideas regarding how/why disparities in OA treatment and care exist and how they can be addressed. Panelists and speakers highlighted mechanisms through which behavioral and biomedical science integration can lead to better health in OA.

NIBIB-funded researchers are developing an implantable, biodegradable film that helps to regenerate the native cartilage at the site of damage. Their study, performed in rabbits, could be an initial, important step in the establishment of a new treatment for this common condition, osteoarthritis.

The FDA approved Olumiant (baricitinib) oral tablets to treat adult patients with severe alopecia areata. The action marks the first FDA approval of a systemic treatment (i.e. treats the entire body rather than a specific location) for alopecia areata.

NIAMS held a roundtable discussion (September 2022) focused on regenerative medicine approaches for cartilage preservation and restoration in knee osteoarthritis (OA). Researchers, clinicians and FDA and patient representatives met virtually with NIAMS leadership to discuss where and how the institute could facilitate progress in the field.